share print

EXECUTIVE LEADERSHIP TEAM

Together, our nine members of the Executive Leadership Team are responsible for worldwide operations. This experienced management team has a proven track record and a core focus on customer excellence and financial performance.
Since 2017, David Wright, has been HRA Pharma's Chief Executive Officer and President of the Executive Leadership Team. Together, our members inspire HRA Pharma teams to dream, dare, share.

David Wright

David Wright

Chief Executive Officer

David Wright is HRA Pharma's Chief Executive Officer and President of the Executive Leadership Team.

 

David Wright joined HRA Pharma in 2017. Former Senior Vice President Global OTC operations of Boehringer-Ingelheim Consumer Healthcare, he has 25 years of professional experience in the field of consumer healthcare. He started his career at Boots Consumer Healthcare prior to joining Sandoz (formerly Novartis) in 1992 as Sales Director. In 1997, David Wright took over as UK Director of Boehringer-Ingelheim Consumer Healthcare, before becoming Global Marketing Director in 2004, and Senior Vice President Global OTC operations in 2010. In this capacity, he had a global responsibility over Boehringer Ingelheim’s activities in the OTC space, with sales in 63 countries (1.8 billion EUR in turnover).

 


 

David Wright joined HRA Pharma in 2017. Former Senior Vice President Global OTC operations of Boehringer-Ingelheim Consumer Healthcare, he has 25 years of professional experience in the field of consumer healthcare. He started his career at Boots Consumer Healthcare prior to joining Sandoz (formerly Novartis) in 1992 as Sales Director. In 1997, David Wright took over as UK Director of Boehringer-Ingelheim Consumer Healthcare, before becoming Global Marketing Director in 2004, and Senior Vice President Global OTC operations in 2010. In this capacity, he had a global responsibility over Boehringer Ingelheim’s activities in the OTC space, with sales in 63 countries (1.8 billion EUR in turnover).

 

-->

Key knowledge:

David Wright

David Wright

UNITED KINGDOM

Chief Executive Officer

David Wright is HRA Pharma's Chief Executive Officer and President of the Executive Leadership Team. David Wright joined HRA Pharma in 2017. Former Senior Vice President Global OTC operations of Boehringer-Ingelheim Consumer Healthcare, he has 25 years of professional experience in the field of consumer healthcare. He started his career at Boots Consumer Healthcare prior to joining Sandoz (formerly Novartis) in 1992 as Sales Director. In 1997, David Wright took over as UK Director of Boehringer-Ingelheim Consumer Healthcare, before becoming Global Marketing Director in 2004, and Senior Vice President Global OTC operations in 2010. In this capacity, he had a global responsibility over Boehringer Ingelheim’s activities in the OTC space, with sales in 63 countries (1.8 billion EUR in turnover).

Geoff Allan

Geoff Allan

Chief Financial Officer

Geoff Allan joined HRA Pharma as Chief Financial Officer and member of the Executive Leadership Team in November 2011.


Prior to this, Mr. Allan served for five years as CFO of Kewego, a leading International provider of internet based video broadcasting solutions. He was responsible for all financial, legal and administrative aspects of the business and participated actively in making Kewego the first profitable company in its sector, in all fund raising and investor relations activities as well as in the sale negotiations.
Before to this, Geoff Allan occupied various senior financial management positions in different service and technology businesses, in particular as CFO of the 3i and Edmond de Rothschild backed Franco-US firm, eDevice, and prior to that working directly for leading French entrepreneurs such as André Rousselet, Founder of Canal +.

Geoff Allan began his career as a financial analyst for an independent stock market listed investment firm, prior to joining the mergers and acquisitions department of The Chase Manhattan Bank in Paris. Geoff has worked on many fund raising and mergers and acquisitions transactions, involving both private and public operations. Geoff holds honours degrees in Law from King's College, University of London and from the University of Paris I, Pantheon – Sorbonne.

Key knowledge:

Geoff Allan

Geoff Allan

UNITED KINGDOM

Chief Financial Officer

Geoff Allan joined HRA Pharma as Chief Financial Officer and member of the Executive Leadership Team in November 2011. Prior to this, Mr. Allan served for five years as CFO of Kewego, a leading International provider of internet based video broadcasting solutions. He was responsible for all financial, legal and administrative aspects of the business and participated actively in making Kewego the first profitable company in its sector, in all fund raising and investor relations activities as well as in the sale negotiations. Before to this, Geoff Allan occupied various senior financial management positions in different service and technology businesses, in particular as CFO of the 3i and Edmond de Rothschild backed Franco-US firm, eDevice, and prior to that working directly for leading French entrepreneurs such as André Rousselet, Founder of Canal +. Geoff Allan began his career as a financial analyst for an independent stock market listed investment firm, prior to joining the mergers and acquisitions department of The Chase Manhattan Bank in Paris. Geoff has worked on many fund raising and mergers and acquisitions transactions, involving both private and public operations. Geoff holds honours degrees in Law from King's College, University of London and from the University of Paris I, Pantheon – Sorbonne.

Anne-Laure Astecker

Anne-Laure Astecker

Regulatory and Compliance Director, Qualified Person

Anne-Laure Astecker has been Regulatory and Compliance Director of HRA Pharma since 2013. In this role she leads the development and implementation of the global regulatory and quality strategies. As Qualified Person of HRA Pharma, Anne-Laure is a member of the Executive Leadership Team of the company.

Anne-Laure Astecker joined HRA Pharma in 2008 as regulatory officer and then moved to the position of head of regulatory affairs. Before joining HRA Pharma, Ms. Astecker was in charge of a Development Registration Center in Austria. Prior to that, she acquired experience in regulatory activities within Aventis Pharma in Paris France and GlaxoSmithKline in the UK.


Ms. Astecker graduated in 2001 with a pharmacy degree from University of Rennes, France and with a Master of international drug development and registration from University of Châtenay-Malabry, Paris XI France.

 

 

 

Key knowledge:

Anne-Laure Astecker

Anne-Laure Astecker

FRANCE

Regulatory and Compliance Director, Qualified Person

Anne-Laure Astecker has been Regulatory and Compliance Director of HRA Pharma since 2013. In this role she leads the development and implementation of the global regulatory and quality strategies. As Qualified Person of HRA Pharma, Anne-Laure is a member of the Executive Leadership Team of the company. Anne-Laure Astecker joined HRA Pharma in 2008 as regulatory officer and then moved to the position of head of regulatory affairs. Before joining HRA Pharma, Ms. Astecker was in charge of a Development Registration Center in Austria. Prior to that, she acquired experience in regulatory activities within Aventis Pharma in Paris France and GlaxoSmithKline in the UK. Ms. Astecker graduated in 2001 with a pharmacy degree from University of Rennes, France and with a Master of international drug development and registration from University of Châtenay-Malabry, Paris XI France.

Florian Battung

Florian Battung

Chief Corporate Development and Strategy Officer

Florian Battung was appointed Chief Corporate Development and Strategy Officer in November 2017. He is a member of the Executive Leadership Team of HRA Pharma.

 

Florian Battung graduated from the École des Mines d’Albi as a Process Engineer. He has a very strong background in product development, project management and portfolio management.

 

He started his career at Ethypharm, first as Development Project Manager then as Head of Development Operations. In 2004, Florian joined Novartis, where he worked on various initiatives aimed at introducing new technologies in process development and manufacturing with the MIT and FDA. He joined HRA Pharma in 2008 as Pharmaceutical Development Officer before being promoted to Head of Pharmaceutical Development, while leading several projects. He was then appointed as R&D Portfolio Director in charge of the oversight of R&D projects and portfolio valuation. He joined the Corporate Development team as Portfolio Management Director when the department was created in 2015. Following his instrumental role in the acquisition of Compeed, Florian was promoted Chief Corporate Development and Strategy Officer in November 2017.

 

 

 

Key knowledge:

Florian Battung

Florian Battung

FRANCE

Chief Corporate Development and Strategy Officer

Florian Battung was appointed Chief Corporate Development and Strategy Officer in November 2017. He is a member of the Executive Leadership Team of HRA Pharma. Florian Battung graduated from the École des Mines d’Albi as a Process Engineer. He has a very strong background in product development, project management and portfolio management. He started his career at Ethypharm, first as Development Project Manager then as Head of Development Operations. In 2004, Florian joined Novartis, where he worked on various initiatives aimed at introducing new technologies in process development and manufacturing with the MIT and FDA. He joined HRA Pharma in 2008 as Pharmaceutical Development Officer before being promoted to Head of Pharmaceutical Development, while leading several projects. He was then appointed as R&D Portfolio Director in charge of the oversight of R&D projects and portfolio valuation. He joined the Corporate Development team as Portfolio Management Director when the department was created in 2015. Following his instrumental role in the acquisition of Compeed, Florian was promoted Chief Corporate Development and Strategy Officer in November 2017.

Paul Carter

Paul Carter

Chief Scientific Officer

Paul Carter has been Chief Scientific Officer at HRA Pharma since October 2017. He is a member of the Executive Leadership Team of HRA Pharma.


He is British by birth, but in addition holds German citizenship after living and working there for over 25 years. He is an Organic Chemist by training, holding B.Sc. and Ph.D. degrees from Southampton University, UK. He also spent 2 years as a Post-Doctoral student at the University of Indiana, USA.


Paul Carter has a particularly strong background in Consumer HealthCare. Since 2010, he was a part of Boehringer Ingelheim’s Executive Leadership Team responsible for the Consumer Health Care business with, as Global Vice President, responsibility for Development, Medicine, and Regulatory Affairs activities. Prior to this he worked for Boehringer Ingelheim in a number of positions; especially, he led the International Project Management activities for BI’s New Chemical Entity projects in the Therapeutic Areas of Virology and CNS diseases. Before 2000, when he moved into these roles in Development in the Pharmaceutical Industry, he had held various roles in research and development in a number of agrochemical companies.

Key knowledge:

Paul Carter

Paul Carter

GERMANY UNITED KINGDOM

Chief Scientific Officer

Paul Carter has been Chief Scientific Officer at HRA Pharma since October 2017. He is a member of the Executive Leadership Team of HRA Pharma. He is British by birth, but in addition holds German citizenship after living and working there for over 25 years. He is an Organic Chemist by training, holding B.Sc. and Ph.D. degrees from Southampton University, UK. He also spent 2 years as a Post-Doctoral student at the University of Indiana, USA. Paul Carter has a particularly strong background in Consumer HealthCare. Since 2010, he was a part of Boehringer Ingelheim’s Executive Leadership Team responsible for the Consumer Health Care business with, as Global Vice President, responsibility for Development, Medicine, and Regulatory Affairs activities. Prior to this he worked for Boehringer Ingelheim in a number of positions; especially, he led the International Project Management activities for BI’s New Chemical Entity projects in the Therapeutic Areas of Virology and CNS diseases. Before 2000, when he moved into these roles in Development in the Pharmaceutical Industry, he had held various roles in research and development in a number of agrochemical companies.

Martyn Hilton

Martyn Hilton

Chief Global Commercial Officer

Martyn Hilton is the company’s Chief Global Commercial Officer and member of the Executive Leadership Team.


He joined HRA Pharma in 2017. Former Global Head of Trade and Shopper at Boehringer-Ingelheim Consumer Healthcare, he is a highly accomplished sales professional with almost 20 years of professional experience working in Consumer Health and FMCG companies across Europe, North America, Latin America, Middle East and Asia Pacific. He started his career in marketing at Boots the Chemists, then held senior customer management positions for Boots Healthcare International. In 2006 he joined Reckitt Benckiser, a company within which he held successive positions, first as Global Sales Development Manager then as Global Trade Marketing Director (Healthcare), Global Customer Marketing Director (Healthcare and Wellbeing) and finally Sales Director at Reckitt Benckiser Thailand.

 

Martyn holds an honours BA degree from the Nottingham Trent University.

Key knowledge:

Martyn Hilton

Martyn Hilton

UNITED KINGDOM

Chief Global Commercial Officer

Martyn Hilton is the company’s Chief Global Commercial Officer and member of the Executive Leadership Team. He joined HRA Pharma in 2017. Former Global Head of Trade and Shopper at Boehringer-Ingelheim Consumer Healthcare, he is a highly accomplished sales professional with almost 20 years of professional experience working in Consumer Health and FMCG companies across Europe, North America, Latin America, Middle East and Asia Pacific. He started his career in marketing at Boots the Chemists, then held senior customer management positions for Boots Healthcare International. In 2006 he joined Reckitt Benckiser, a company within which he held successive positions, first as Global Sales Development Manager then as Global Trade Marketing Director (Healthcare), Global Customer Marketing Director (Healthcare and Wellbeing) and finally Sales Director at Reckitt Benckiser Thailand. Martyn holds an honours BA degree from the Nottingham Trent University.

Sophie Lacourrege

Sophie Lacourrege

Chief of Human Resources and Communication Officer

Sophie Lacourrege is the company’s Chief of Human Resources and Communication Officer and member of the Executive Leadership Team.

Sophie Lacourrege has joined the company in 2017. She is a senior manager operating in international environments with 20 years of experience in people and organizations’ development, change management, employment relations and project management. She joined HRA Pharma from the French subsidiary of Celgene where she was Human Resources Director, a role she has held for 9 years. 


Ms. Lacourrege holds a diploma of Institut d’Etudes Politiques from Science Pô Bordeaux, a Master's degree of Labour Law from University of Bordeaux I, and a postgraduate degree in “Human Resources Management & Employement Relations” from the University of Social Sciences in Toulouse.

 

Key knowledge:

Sophie Lacourrege

Sophie Lacourrege

FRANCE

Chief of Human Resources and Communication Officer

Sophie Lacourrege is the company’s Chief of Human Resources and Communication Officer and member of the Executive Leadership Team. Sophie Lacourrege has joined the company in 2017. She is a senior manager operating in international environments with 20 years of experience in people and organizations’ development, change management, employment relations and project management. She joined HRA Pharma from the French subsidiary of Celgene where she was Human Resources Director, a role she has held for 9 years. Ms. Lacourrege holds a diploma of Institut d’Etudes Politiques from Science Pô Bordeaux, a Master's degree of Labour Law from University of Bordeaux I, and a postgraduate degree in “Human Resources Management & Employement Relations” from the University of Social Sciences in Toulouse.

Frédérique Welgryn

Frédérique Welgryn

Chief Strategic Operations and Innovation Officer

Frédérique Welgryn has been Chief Strategic Operations and Innovation Officer since January 2018. She is a member of the Executive Leadership Team of HRA Pharma.

Frédérique Welgryn was Chief Operating Officer from 2016 to 2017. In that role she was responsible for overseeing ongoing business operations within the company and creating operations strategy and policies. Prior to that Frederique served for four years as HRA Pharma's Women's Health Therapeutic Domain Director. In that role, she was responsible for providing commercial leadership and maximizing the value of the company's Women's Health activities. Ms. Welgryn began her career with HRA Pharma in 2010 as the Operations Director of the company's French subsidiary. Before joining HRA Pharma, she held various leadership positions as Marketing & Sales Director and Business Units Manager with large pharmaceutical companies such as Roche, Sanofi and AstraZeneca. She also served as managing consultant for the Strategy and Transformation Division of CAP Gemini Ernst & Young.

 

Ms. Welgryn graduated with a Bachelor of Science in Pharmacy and a master in Pharmaceutical Marketing and Management from Paris V University (France). She completed her MSc in Management at HEC Paris Business School (Ecole des hautes études commerciales de Paris, France).

Key knowledge:

Frédérique Welgryn

Frédérique Welgryn

FRANCE

Chief Strategic Operations and Innovation Officer

Frédérique Welgryn has been Chief Strategic Operations and Innovation Officer since January 2018. She is a member of the Executive Leadership Team of HRA Pharma. Frédérique Welgryn was Chief Operating Officer from 2016 to 2017. In that role she was responsible for overseeing ongoing business operations within the company and creating operations strategy and policies. Prior to that Frederique served for four years as HRA Pharma's Women's Health Therapeutic Domain Director. In that role, she was responsible for providing commercial leadership and maximizing the value of the company's Women's Health activities. Ms. Welgryn began her career with HRA Pharma in 2010 as the Operations Director of the company's French subsidiary. Before joining HRA Pharma, she held various leadership positions as Marketing & Sales Director and Business Units Manager with large pharmaceutical companies such as Roche, Sanofi and AstraZeneca. She also served as managing consultant for the Strategy and Transformation Division of CAP Gemini Ernst & Young. Ms. Welgryn graduated with a Bachelor of Science in Pharmacy and a master in Pharmaceutical Marketing and Management from Paris V University (France). She completed her MSc in Management at HEC Paris Business School (Ecole des hautes études commerciales de Paris, France).

Richard Westcott

Richard Westcott

Chief Supply Chain, IT and Facilities Officer

Richard Westcott has been Chief Supply Chain, IT and Facilities Officer since December 2017. He is a member of the Executive Leadership Team.

 

Richard Westcott is a Chartered Engineer with a BSc Engineering degree from Manchester University and an MBA from Nottingham Business School. He is a Fellow of the” Institution of Mechanical Engineers” and a member of the “Fédération Européenne d'Associations Nationales d'Ingénieurs”.

 

Former Head of Methods & Standards Europe & Asia Pacific at Crown Holdings Inc., he is an experienced operations and supply chain professional with over 35 years’ experience working in brand building packaging products for consumer marketing companies, FMCG and the pharmaceutical industry. He started his career in pharmaceutical manufacturing at the Boots Company PLC before joining the Mars Group in FMCG production and project management capacities. In 1994 he joined Crown Holdings Inc. as General Manager of a UK manufacturing business unit and has held positions within Crown such as European Industrial Investment Manager, Manufacturing & Logistics Director and Supply Chain Director for the European Aerosols Sector and finally Head of the Corporate Department of Methods & Standards responsible for the European and Asia Pacific Divisions.

 

 

Key knowledge:

Richard Westcott

Richard Westcott

UNITED KINGDOM

Chief Supply Chain, IT and Facilities Officer

Richard Westcott has been Chief Supply Chain, IT and Facilities Officer since December 2017. He is a member of the Executive Leadership Team. Richard Westcott is a Chartered Engineer with a BSc Engineering degree from Manchester University and an MBA from Nottingham Business School. He is a Fellow of the” Institution of Mechanical Engineers” and a member of the “Fédération Européenne d'Associations Nationales d'Ingénieurs”. Former Head of Methods & Standards Europe & Asia Pacific at Crown Holdings Inc., he is an experienced operations and supply chain professional with over 35 years’ experience working in brand building packaging products for consumer marketing companies, FMCG and the pharmaceutical industry. He started his career in pharmaceutical manufacturing at the Boots Company PLC before joining the Mars Group in FMCG production and project management capacities. In 1994 he joined Crown Holdings Inc. as General Manager of a UK manufacturing business unit and has held positions within Crown such as European Industrial Investment Manager, Manufacturing & Logistics Director and Supply Chain Director for the European Aerosols Sector and finally Head of the Corporate Department of Methods & Standards responsible for the European and Asia Pacific Divisions.

closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?